1
TI  - PREVENTION OF ENDOTOXIN-INDUCED MONOKINE RELEASE BY HUMAN LOW- AND
HIGH-DENSITY LIPOPROTEINS AND BY APOLIPOPROTEIN A-I.
AU  - FLEGEL WA
AU  - BAUMSTARK MW
AU  - WEINSTOCK C
AU  - BERG A
AU  - NORTHOFF H
AD  - ABTEILUNG FUR TRANSFUSIONSMEDIZIN, UNIVERSITAT ULM, GERMANY.
SO  - INFECTION & IMMUNITY 1993 DEC;61(12):5140-6
AB  - Interaction of endotoxin (lipopolysaccharide [LPS]) with human
lipoproteins is known to prevent the LPS-induced activation of human
monocytes and release of cytokines (monokines). LPS was exposed to
lipoprotein classes separated by ultracentrifugation and to
apolipoprotein A-I. Then monocytes were added, and the LPS
activation of monocytes was determined by measuring the induced
monokines. Failure of LPS to induce monokine release was called LPS
inactivation caused by lipoproteins or apolipoproteins. The LPS
inactivation is shown to be a function of low-density lipoproteins.
High-density lipoproteins inactivate LPS to a much lesser extent.
The very-low-density lipoproteins cannot inactivate LPS. Lipid
components seemed not absolutely required for LPS inactivation,
because purified human apolipoprotein A-I without its physiological
lipid complement also inhibits LPS-induced monokine release.
MH  - ADULT
MH  - APOLIPOPROTEIN A-I/PD [PHARMACOLOGY]
MH  - BLOOD PROTEINS/PD [PHARMACOLOGY]
MH  - ENDOTOXINS/AI [ANTAGONISTS & INHIBITORS]
MH  - *ENDOTOXINS/PD [PHARMACOLOGY]
MH  - HUMAN
MH  - IN VITRO
MH  - INTERLEUKIN-1/SE [SECRETION]
MH  - INTERLEUKIN-6/SE [SECRETION]
MH  - KINETICS
MH  - LIPOPOLYSACCHARIDES/PD [PHARMACOLOGY]
MH  - LIPOPROTEINS/AI [ANTAGONISTS & INHIBITORS]
MH  - *LIPOPROTEINS/PD [PHARMACOLOGY]
MH  - LIPOPROTEINS, HDL/PD [PHARMACOLOGY]
MH  - LIPOPROTEINS, LDL/PD [PHARMACOLOGY]
MH  - MONOCYTES/DE [DRUG EFFECTS]
MH  - MONOCYTES/IM [IMMUNOLOGY]
MH  - MONOCYTES/SE [SECRETION]
MH  - *MONOKINES/SE [SECRETION]
MH  - SUPPORT, NON-U.S. GOV'T
MH  - TUMOR NECROSIS FACTOR/SE [SECRETION]
JC  - GO7